BioAge LabsvsJohnson & Johnson

BIOA and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

BioAge Labs (BIOA) has a market value of $226M and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, BIOA moved -34.6% and JNJ +45.4%. Dividend yield: BIOA none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BIOA$226M

    JNJ$672B

    JNJ is 2,967 times BIOA

  • Revenue, 12 months

    BIOA$8.6M

    JNJ$99.3B

    JNJ is 11,552 times BIOA

  • Net income, 12 months

    BIOA-$108M

    JNJ$16.1B

  • Operating margin

    BIOA-1,401.8%

    JNJ–

  • ROIC

    BIOA-28.7%

    JNJ12.4%

    41.1 points apart

  • P/E

    BIOA–

    JNJ41.7

  • Dividend yield

    BIOA0.0%

    JNJ1.9%

    1.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BIOA-34.6%

JNJ+45.4%

100200300DecFebAprJunAugOct
Returns by period
PeriodBIOAWith dividendsJNJWith dividends
1 year since November 14, 2025-34.6%Price -34.6%+45.4%Price +42.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BIOABioAge LabsJNJJohnson & Johnson

Valuation

BIOAJNJ
Valuation
Price$5.10$278.70
Market value$226M$672B
Enterprise value (EV)–$699B
P/E–41.7
P/E, 5-year median–21.9
P/B0.78.2
EV/EBIT–39.4
Free cash flow yield–3.1%

Results and growth

BIOAJNJ
Results and growth
Revenue, 12 months$8.6M$99.3B
Net income, 12 months-$108M$16.1B
Free cash flow, 12 months-$103M$20.6B
Earnings per share, 12 months-$2.55$6.59
Revenue growth, year on year–6.1%
Revenue growth a year, past–+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

BIOAJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-1,401.8%–
Net margin-1,253.6%16.2%
ROIC-28.7%12.4%
ROE-32.7%19.7%

Balance sheet

BIOAJNJ
Balance sheet
Cash$284M$17.2B
Total debt$2.7M$44.7B
Net debt / EBITDA–1.1
Interest cover-913.2×18.0×

Dividends and buybacks

BIOAJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BIOA or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, BioAge Labs or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 2,967.4 times BioAge Labs ($226M), at today's prices.

How did BIOA and JNJ stock do over the last 1 years?

Since November 14, 2025, BIOA's price moved -34.6% and JNJ's +42.2%. With dividends: BIOA -34.6% (-34.6% a year), JNJ +45.4% (+45.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, BIOA or JNJ?

The dividend yield at today's price is none for BioAge Labs and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, BioAge Labs or Johnson & Johnson?

Over the last twelve months, the net margin was -1,253.6% for BioAge Labs and 16.2% for Johnson & Johnson, and the operating margin -1,401.8% and –. Revenue was $8.6M and $99.3B.

Which is the better investment, BioAge Labs or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.